What are the various Epstein‑Barr virus antibodies (viral capsid antigen IgM, viral capsid antigen IgG, Epstein‑Barr nuclear antigen IgG, early antigen IgG) and when do they typically develop during infection?

Epstein-Barr Virus Antibody Development and Interpretation

VCA IgM appears first (within the first 10 days of symptoms), followed by VCA IgG which appears very early and persists for life, while EBNA-1 IgG develops late (typically after 20-30 days) and indicates past infection; EA IgG appears in some acute cases but is less reliable for routine diagnosis.

Antibody Timeline and Clinical Significance

Viral Capsid Antigen (VCA) Antibodies

VCA IgM:

• Appears at disease onset, typically within the first 10 days of clinical symptoms 12
• Usually disappears during the second month of infection 1
• Serves as the primary marker of acute infection
• Critical caveat: VCA IgM can persist or reactivate, creating diagnostic confusion—in one study, 23% of patients with VCA IgM actually had reactivation rather than primary infection 3
• When VCA IgM is present alongside VCA IgG and EBNA-1 IgG, only 42% had true primary infection 3

VCA IgG:

• Appears very early in infection, often before symptoms develop 1
• Persists for life at high levels 4
• Initially low-avidity antibodies that mature over 20-30 days to high-avidity 2
• More than 90% of sera show avidity index below 0.25 during the first 10 days 2
• High-avidity VCA IgG indicates past infection, not acute disease 23

Epstein-Barr Nuclear Antigen (EBNA-1) IgG

• Appears late in the disease course, typically 20-30 days or more after symptom onset 12
• Absence of EBNA-1 IgG in the presence of VCA IgM and VCA IgG strongly suggests acute primary infection
• Presence indicates past infection or late primary infection 5
• Persists for life once developed 4

Early Antigen (EA) IgG

• Occurs in approximately 25 patients with infectious mononucleosis, but only 9 had high titers in one series 1
• Present in the majority of chronically ill persons 4
• EA IgG avidity may remain low even when VCA IgG avidity is already high, allowing further differentiation of acute versus recent infection 2
• Less reliable as a routine diagnostic marker compared to VCA and EBNA-1 antibodies

Diagnostic Algorithm for EBV Infection Status

Primary Acute Infection:

• VCA IgM positive + VCA IgG positive + EBNA-1 IgG negative
• Low-avidity VCA IgG (if tested)
• Heterophile antibodies positive in 94% of cases 3

Late Primary or Recent Infection:

• VCA IgM positive + VCA IgG positive + EBNA-1 IgG positive
• Requires avidity testing to distinguish from reactivation
• Low to intermediate avidity VCA IgG suggests late primary infection 23

Past Infection (Remote):

• VCA IgM negative + VCA IgG positive + EBNA-1 IgG positive
• High-avidity VCA IgG 2
• This is the most common pattern in previously infected individuals

No Prior Infection:

• All antibodies negative

Critical Pitfalls to Avoid

1. Do not rely solely on VCA IgM for acute infection diagnosis—it can persist or reactivate, leading to false interpretation of primary infection when reactivation is actually occurring 3

2. Heterophile antibody testing is highly valuable—presence strongly supports primary infection (94% sensitivity), while absence in patients with VCA IgM/IgG/EBNA-1 positivity suggests reactivation rather than primary infection 3

3. Consider avidity testing when all three antibodies are positive—this resolves the ambiguity between late primary infection and reactivation, as high-avidity IgG indicates past infection with current reactivation 23

4. EBNA-1 IgG can be lost during cellular immune suppression, creating diagnostic confusion in immunocompromised patients 2

5. In children, heterophile antibodies may be absent even in true primary infection, making EBV-specific antibody patterns more critical 1